Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

GT Biopharma Inc. (GTBP)

Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski, BDavid5
Search This Board: 
Last Post: 9/25/2017 5:41:13 PM - Followers: 174 - Board type: Free - Posts Today: 0


Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!


Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.



Company Website


Corporate Overview - Presentation
Fall 2015
Click the link:





OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet




Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.


Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.


Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.


Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.


Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.


Stock Information:

Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#11253   worth $1 as it sits ( $2 max.) munimi 09/25/17 05:41:13 PM
#11252   OXIS was very good to me, and my simon wagstaff 09/21/17 10:46:27 AM
#11251   Down 80% since r/s and "merger". Thought this Gibba 09/21/17 09:54:36 AM
#11250   OXISD has rallied over 9% today off of Oharper 09/19/17 11:06:36 AM
#11248   "Since neurological diseases are disorders of the brain, billymack 09/19/17 10:34:45 AM
#11247   Effective Sept. 20,2017 OXISD will change to GTBP: Renee 09/19/17 08:43:10 AM
#11246   OXISD Welcomes Thomas N. Chase, MD BDavid5 09/19/17 08:35:27 AM
#11245   Covered again, Oxis has been good to me. simon wagstaff 09/18/17 12:22:36 PM
#11244   Ooh, another reverse split before uplifting? simon wagstaff 09/18/17 11:25:37 AM
#11243   Welcome All New Huckle-Berrries. GLTY Gibba 09/18/17 10:33:58 AM
#11242   Better uplist soon, before it's below 5 bucks simon wagstaff 09/18/17 07:55:34 AM
#11241   5:00 am posts, must keep some people awake. simon wagstaff 09/18/17 07:53:17 AM
#11240   Nice post , Oxisd is the real deal. simmons420 09/18/17 07:05:18 AM
#11239   BTW, I went to look at IOVA's SEC Johnny B Good 09/18/17 04:53:02 AM
#11238   I did my DD. Did you, really? Johnny B Good 09/18/17 04:53:01 AM
#11237   I have to admit, I was skeptical at Johnny B Good 09/18/17 04:35:45 AM
#11236   I think they are too crooked to uplist Gibba 09/17/17 05:40:09 PM
#11235   Good question. Clear as mud. mta65 09/15/17 05:03:01 PM
#11234   Gibba, looks like a catch-up Form D filing mta65 09/15/17 05:01:44 PM
#11233   Just what exactly do they have going in simon wagstaff 09/15/17 04:50:06 PM
#11232   Odd-Ball Filings. What was the one today? Can Gibba 09/15/17 04:12:44 PM
#11231   $550k for "promotions" to last until 10/1/17? Gibba 09/15/17 04:11:47 PM
#11230   I would have to disagree no pump over Suarezzz1111 09/15/17 03:43:03 PM
#11229   Thanks me big boss - know it all Axel 09/15/17 01:08:07 PM
#11228   I don't know what you are referencing as Suarezzz1111 09/15/17 12:39:26 PM
#11227   Bulgarian fake news factory? simon wagstaff 09/15/17 12:34:47 PM
#11226   If OXISD does officially up list to a Suarezzz1111 09/15/17 12:24:01 PM
#11225   $13 a share only if $550k in bunk Gibba 09/15/17 11:51:15 AM
#11224   Yes, I see it in action. That's simon wagstaff 09/15/17 11:46:12 AM
#11223   I'm adding on dips i also believe they simmons420 09/15/17 11:44:25 AM
#11222   IMO if OXISD does get up listed that Suarezzz1111 09/15/17 11:42:58 AM
#11221   I agree this is like no other penny simmons420 09/15/17 11:40:25 AM
#11220   Did you read the footer of the last mta65 09/15/17 11:22:17 AM
#11219   As we watch for this rebound off of Suarezzz1111 09/15/17 11:19:15 AM
#11218   I sure did! I suggest further research. Charts simon wagstaff 09/15/17 10:05:44 AM
#11217   We'll see. Learn how to read charts. BobDoleYahoo 09/15/17 09:47:15 AM
#11216   No way it'll see 13 again Axel 09/15/17 06:34:56 AM
#11215   Looks like a technical bounce to $13 range BobDoleYahoo 09/15/17 02:01:26 AM
#11214   Never seen a email like this before any ideas Bishop123 09/14/17 09:01:41 PM
#11213   Couldn't at the retail level until the reverse split. simon wagstaff 09/14/17 01:12:09 PM
#11212   This Biotech Trend Could Indicate The Next 4-Year billymack 09/14/17 12:05:49 PM
#11211   And that would be my luck how do Bishop123 09/14/17 11:56:25 AM
#11209   Massive dilution on the way. simon wagstaff 09/14/17 10:50:41 AM
#11208   I agree is OXISD very volatile right now Suarezzz1111 09/14/17 10:45:59 AM
#11207   MCET demonstrated just how far you can go simon wagstaff 09/14/17 10:39:38 AM
#11206   I think volume is needed for scalping. billymack 09/14/17 10:36:09 AM
#11205   OXISD I'm playing the trade. The stock is BDavid5 09/14/17 10:13:07 AM
#11204   Already have, a couple of times. No matter simon wagstaff 09/14/17 10:08:47 AM
#11203   This is going down to one dollar - Gibba 09/14/17 10:06:41 AM
#11201   I read all posts as we are all mta65 09/14/17 08:56:11 AM